Doxorubicin and Ifosfamide in Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: A Phase II Study of the Genitourinary Group of the French Federation of Cancer Centers
2002; Lippincott Williams & Wilkins; Volume: 168; Issue: 3 Linguagem: Inglês
10.1016/s0022-5347(05)64551-x
ISSN1527-3792
AutoresBernard Escudier, Jean‐Pierre Droz, Frédéric Rolland, Marie-Josée Terrier-Lacombe, Gwénaëlle Gravis, Philippe Beuzeboc, B. Chauvet, Christine Chevreau, J.C. Eymard, Thierry Lesimple, Yacine Merrouche, Stéphane Oudard, Frank Priou, C. Guillemare, Sophie Gourgou, Stéphane Culine,
Tópico(s)Bladder and Urothelial Cancer Treatments
ResumoNo AccessJournal of UrologyCLINICAL UROLOGY: ORIGINAL ARTICLES1 Sep 2002Doxorubicin and Ifosfamide in Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: A Phase II Study of the Genitourinary Group of the French Federation of Cancer Centers B. Escudier, J.P. Droz, F. Rolland, M.J. Terrier-Lacombe, G. Gravis, P. Beuzeboc, B. Chauvet, C. Chevreau, J.C. Eymard, T. Lesimple, Y. Merrouche, S. Oudard, F. Priou, C. Guillemare, S. Gourgou, and S. Culine B. EscudierB. Escudier , J.P. DrozJ.P. Droz , F. RollandF. Rolland , M.J. Terrier-LacombeM.J. Terrier-Lacombe , G. GravisG. Gravis , P. BeuzebocP. Beuzeboc , B. ChauvetB. Chauvet , C. ChevreauC. Chevreau , J.C. EymardJ.C. Eymard , T. LesimpleT. Lesimple , Y. MerroucheY. Merrouche , S. OudardS. Oudard , F. PriouF. Priou , C. GuillemareC. Guillemare , S. GourgouS. Gourgou , and S. CulineS. Culine View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)64551-XAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We assessed the efficacy and toxicity of a chemotherapy regimen combining doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma. Materials and Methods: Of the 25 patients included in a prospective multicenter phase II trial 23 were evaluable for efficacy and toxicity studies after pathological review. Results: A median of 3 cycles per patient (range 1 to 8) was administered. No objective response was observed. Median time to progression was 2.2 months and median overall survival was 3.9 months. A single patient died of toxicity. Conclusions: The results do not support the standard use of doxorubicin/ifosfamide chemotherapy in patients with metastatic sarcomatoid renal cell carcinoma. References 1 : Sarcomatoid renal cell carcinoma: basic biology, clinical behavior response to therapy. Urol Oncol2001; 6: 231. Crossref, Google Scholar 2 : Sarcomatoid renal cell carcinoma: clinicopathologic. A study of 42 cases. Cancer1987; 59: 516. Crossref, Medline, Google Scholar 3 : Sarcomatoid differentiation in renal cell carcinoma. A study of 101 cases. Am J Surg Pathol2001; 25: 275. Crossref, Medline, Google Scholar 4 : Prognostic factors survival of patients with sarcomatoid renal cell carcinoma. J Urol2002; 167: 65. Link, Google Scholar 5 : Treatment of sarcomatoid renal cell carcinoma: is there a role for chemotherapy?. Eur Urol1995; 27: 138. Crossref, Medline, Google Scholar 6 : Reporting results of cancer treatment. Cancer1981; 47: 207. Crossref, Medline, Google Scholar 7 : Chemoimmunotherapy of sarcomatoid renal cell carcinoma. Med Pediatr Oncol1978; 5: 9. Crossref, Medline, Google Scholar 8 : Sarcomatoid renal cell carcinoma. A treatable entity. Cancer1987; 60: 1313. Crossref, Medline, Google Scholar 9 : Phase II trial of combination chemotherapy with dacarbazine, cyclophosphamide, cisplatin, doxorubicin, vindesine (DECAV) in advanced renal cell cancer. Urology1989; 34: 281. Crossref, Medline, Google Scholar 10 : Sustained response of sarcomatoid renal-cell carcinoma to MAID chemotherapy: case report review of the literature. Ann Oncol2001; 12: 271. Crossref, Medline, Google Scholar 11 : Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, response to combined surgical resection immunotherapy. J Clin Oncol1999; 17: 523. Crossref, Medline, Google Scholar 12 : Mutations of the p53 gene p53 protein overexpression are associated with sarcomatoid transformation in renal cell carcinomas. Cancer Res1995; 55: 658. Medline, Google Scholar 13 : SPARC expression in primary human renal cell carcinoma: upregulation of SPARC in sarcomatoid renal carcinoma. Hum Pathol2001; 32: 1064. Crossref, Medline, Google Scholar From the Institut Gustave Roussy, Villejuif, Centre Léon Bérard, Lyon, Centre René Gauducheau, Nantes, Institut Paoli Calmettes, Marseille, Institut Curie and Hôtel-Dieu, Paris, Clinique Sainte-Catherine, Avignon, Institut Claudius Régaud, Toulouse, Institut Jean Godinot, Reims, Centre Eugène Marquis, Rennes, Centre Hospitalo-Universitaire, Besancon, Centre Hospitalier, La Roche/Yon and Centre Val d'Aurelle, Montpellier, France© 2002 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited by Al-Juhaishi T, Deng X, Bandyopadhyay D and Paul A The Role of Cytoreductive Nephrectomy and Targeted Therapy on Outcomes of Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: A Population-Based AnalysisCureus, 10.7759/cureus.25395 Fontes-Sousa M and Calvo E (2022) First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid featuresCancer Treatment Reviews, 10.1016/j.ctrv.2022.102374, VOL. 105, (102374), Online publication date: 1-Apr-2022. Quhal F, Mori K, Fajkovic H, Remzi M, Shariat S and Schmidinger M (2021) Immunotherapy-based combinations in the first-line treatment of metastatic renal cell carcinoma with sarcomatoid features: a systematic review and network meta-analysisCurrent Opinion in Urology, 10.1097/MOU.0000000000000940, VOL. 32, NO. 1, (61-68), Online publication date: 1-Jan-2022. Hahn A, Lebenthal J, Genovese G, Sircar K, Tannir N and Msaouel P (2022) The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinomaCancer Treatment and Research Communications, 10.1016/j.ctarc.2022.100640, VOL. 33, (100640), . Candelario N, Geiger C and Flaig T Sarcomatoid Renal Cell Carcinoma: The Present and Future of Treatment ParadigmsKidney Cancer, 10.3233/KCA-210126, VOL. 5, NO. 4, (167-179) Rini B, Motzer R, Powles T, McDermott D, Escudier B, Donskov F, Hawkins R, Bracarda S, Bedke J, De Giorgi U, Porta C, Ravaud A, Parnis F, Grande E, Zhang W, Huseni M, Carroll S, Sufan R, Schiff C and Atkins M (2021) Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical TrialEuropean Urology, 10.1016/j.eururo.2020.06.021, VOL. 79, NO. 5, (659-662), Online publication date: 1-May-2021. Tannir N, Signoretti S, Choueiri T, McDermott D, Motzer R, Flaifel A, Pignon J, Ficial M, Frontera O, George S, Powles T, Donskov F, Harrison M, Barthélémy P, Tykodi S, Kocsis J, Ravaud A, Rodriguez-Cid J, Pal S, Murad A, Ishii Y, Saggi S, McHenry M and Rini B (2021) Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell CarcinomaClinical Cancer Research, 10.1158/1078-0432.CCR-20-2063, VOL. 27, NO. 1, (78-86), Online publication date: 1-Jan-2021. Blum K, Gupta S, Tickoo S, Chan T, Russo P, Motzer R, Karam J and Hakimi A (2020) Sarcomatoid renal cell carcinoma: biology, natural history and managementNature Reviews Urology, 10.1038/s41585-020-00382-9, VOL. 17, NO. 12, (659-678), Online publication date: 1-Dec-2020. George G, Schmidt L, Tolat P, Riese M and Kilari D (2020) Salvage ipilimumab associated with a significant response in sarcomatoid renal cell carcinomaJournal for ImmunoTherapy of Cancer, 10.1136/jitc-2020-000584, VOL. 8, NO. 1, (e000584), Online publication date: 1-Feb-2020. Lázaro M, Valderrama B, Suárez C, de-Velasco G, Beato C, Chirivella I, González-del-Alba A, Laínez N, Méndez-Vidal M and Arranz J (2020) SEOM clinical guideline for treatment of kidney cancer (2019)Clinical and Translational Oncology, 10.1007/s12094-019-02285-7, VOL. 22, NO. 2, (256-269), Online publication date: 1-Feb-2020. Hanif A, Pandey M, Khan S, Attwood K and George S (2019) Metastatic sarcomatoid renal cell carcinoma treated with immune checkpoint inhibitorsOncoImmunology, 10.1080/2162402X.2019.1606639, VOL. 8, NO. 8, Online publication date: 3-Aug-2019. Lebacle C, Pooli A, Bessede T, Irani J, Pantuck A and Drakaki A (2018) Epidemiology, biology and treatment of sarcomatoid RCC: current state of the artWorld Journal of Urology, 10.1007/s00345-018-2355-y, VOL. 37, NO. 1, (115-123), Online publication date: 1-Jan-2019. Delphine B, Damien A and Philippe B (2019) Renal Cell Carcinoma with Sarcomatoid Features Rare Kidney Tumors, 10.1007/978-3-319-96989-3_9, (105-128), . Mouallem N, Smith S and Paul A (2018) Sarcomatoid renal cell carcinoma: Biology and treatment advancesUrologic Oncology: Seminars and Original Investigations, 10.1016/j.urolonc.2017.12.012, VOL. 36, NO. 6, (265-271), Online publication date: 1-Jun-2018. Pang A, Carbini M, Moreira A and Maki R (2018) Carcinosarcomas and Related Cancers: Tumors Caught in the Act of Epithelial-Mesenchymal TransitionJournal of Clinical Oncology, 10.1200/JCO.2017.74.9523, VOL. 36, NO. 2, (210-216), Online publication date: 10-Jan-2018. Liaw B, Mehrazin R, Baker C, Sfakianos J and Tsao C (2017) Management of Atypical Renal Cell CarcinomasCurrent Treatment Options in Oncology, 10.1007/s11864-017-0501-1, VOL. 18, NO. 10, Online publication date: 1-Oct-2017. Keskin S, Msaouel P, Hess K, Yu K, Matin S, Sircar K, Tamboli P, Jonasch E, Wood C, Karam J and Tannir N (2017) Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy ErasJournal of Urology, VOL. 198, NO. 3, (530-537), Online publication date: 1-Sep-2017. Zhang T, Gong J, Maia M and Pal S (2017) Systemic Therapy for Non–Clear Cell Renal Cell CarcinomaAmerican Society of Clinical Oncology Educational Book, 10.1200/EDBK_175572, NO. 37, (337-342), Online publication date: 1-May-2017. Thomas A, Adibi M, Slack R, Borregales L, Merrill M, Tamboli P, Sircar K, Jonasch E, Tannir N, Matin S, Wood C and Karam J (2016) The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Matched Controlled AnalysisJournal of Urology, VOL. 196, NO. 3, (678-684), Online publication date: 1-Sep-2016. Nguyen D, Vilaseca A, Vertosick E, Corradi R, Touijer K, Benfante N, Sjoberg D and Russo P (2015) Histologic subtype impacts cancer-specific survival in patients with sarcomatoid-variant renal cell carcinoma treated surgicallyWorld Journal of Urology, 10.1007/s00345-015-1644-y, VOL. 34, NO. 4, (539-544), Online publication date: 1-Apr-2016. Joseph R, Millis S, Carballido E, Bryant D, Gatalica Z, Reddy S, Bryce A, Vogelzang N, Stanton M, Castle E and Ho T (2015) PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid DifferentiationCancer Immunology Research, 10.1158/2326-6066.CIR-15-0150, VOL. 3, NO. 12, (1303-1307), Online publication date: 1-Dec-2015. Diamond E, Molina A, Carbonaro M, Akhtar N, Giannakakou P, Tagawa S and Nanus D (2015) Cytotoxic chemotherapy in the treatment of advanced renal cell carcinoma in the era of targeted therapyCritical Reviews in Oncology/Hematology, 10.1016/j.critrevonc.2015.08.007, VOL. 96, NO. 3, (518-526), Online publication date: 1-Dec-2015. Eminaga O, Akbarov I, Wille S and Engelmann U (2015) Does postoperative radiation therapy impact survival in non-metastatic sarcomatoid renal cell carcinoma? A SEER-based studyInternational Urology and Nephrology, 10.1007/s11255-015-1093-y, VOL. 47, NO. 10, (1653-1663), Online publication date: 1-Oct-2015. Vera-Badillo F, Templeton A, Duran I, Ocana A, de Gouveia P, Aneja P, Knox J, Tannock I, Escudier B and Amir E (2015) Systemic Therapy for Non–clear Cell Renal Cell Carcinomas: A Systematic Review and Meta-analysisEuropean Urology, 10.1016/j.eururo.2014.05.010, VOL. 67, NO. 4, (740-749), Online publication date: 1-Apr-2015. Yan Y, Liu L, Zhou J, Li L, Li Y, Chen M, Wang L, He W, Guan X, Zu X and Qi L (2014) Clinicopathologic characteristics and prognostic factors of sarcomatoid renal cell carcinomaJournal of Cancer Research and Clinical Oncology, 10.1007/s00432-014-1740-1, VOL. 141, NO. 2, (345-352), Online publication date: 1-Feb-2015. Tantravahi S, Albertson D, Agarwal A, Ravulapati S, Poole A, Patel S, Hawatmeh J, Straubhar A, Liu T, Stenehjem D and Agarwal N (2015) Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell CarcinomaJournal of Oncology, 10.1155/2015/181926, VOL. 2015, (1-6), . Geynisman D and Stadler W (2015) Variant Renal Carcinoma Histologies: Therapeutic Considerations Kidney Cancer, 10.1007/978-3-319-17903-2_21, (345-364), . Miolo G, Ash A, Buonadonna A, Lo Re G, Torrisi E, Cervo S, Santeufemia D, Tuzi A and Canzonieri V (2014) Grade 4 unclassified renal cell carcinoma with sarcomatoid component expressing S-100 protein. A case report with peculiar diagnostic and therapeutic implicationsCancer Biology & Therapy, 10.4161/15384047.2014.956642, VOL. 15, NO. 11, (1439-1443), Online publication date: 2-Nov-2014. Pal S, Jones J, Carmichael C, Saikia J, Hsu J, Liu X, Figlin R, Twardowski P and Lau C (2013) Clinical outcome in patients receiving systemic therapy for metastatic sarcomatoid renal cell carcinoma: A retrospective analysis☆Urologic Oncology: Seminars and Original Investigations, 10.1016/j.urolonc.2012.04.007, VOL. 31, NO. 8, (1826-1831), Online publication date: 1-Nov-2013. Conter H, Lim Z, Ng C, Millikan R and Tannir N (2013) Curability of Poor-Risk Metastatic Sarcomatoid Renal Cell Carcinoma with the Combination of Gemcitabine, 5-Fluorouracil, and Interferon-Alfa: A Case Report of a 55-Year-Old Man with a 10-Year Complete RemissionClinical Genitourinary Cancer, 10.1016/j.clgc.2013.04.005, VOL. 11, NO. 3, (370-373), Online publication date: 1-Sep-2013. Arnoux V, Lechevallier E, Pamela A, Long J and Rambeaud J (2013) Carcinomes rénaux à contingent sarcomatoïdeProgrès en Urologie, 10.1016/j.purol.2013.01.003, VOL. 23, NO. 7, (430-437), Online publication date: 1-Jun-2013. Park I, Cho Y, Lee J, Ahn J, Lee D, Song C, Hong J, Kim C and Ahn H (2013) Prognostic factors of metastatic renal cell carcinoma with extensive sarcomatoid componentJournal of Cancer Research and Clinical Oncology, 10.1007/s00432-013-1386-4, VOL. 139, NO. 5, (817-827), Online publication date: 1-May-2013. Michaelson M, Zhu A, Ryan D, McDermott D, Shapiro G, Tye L, Chen I, Stephenson P, Patyna S, Ruiz-Garcia A and Schwarzberg A (2013) Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding studyBritish Journal of Cancer, 10.1038/bjc.2013.96, VOL. 108, NO. 7, (1393-1401), Online publication date: 1-Apr-2013. Lane B (2013) Prognostic Factors for Localized Renal Cell Carcinoma Renal Cell Carcinoma, 10.1007/978-1-62703-062-5_5, (83-102), . Juan M and Climent M (2012) Long stabilization of sarcomatoid renal cell carcinoma treated with sorafenibActas Urológicas Españolas (English Edition), 10.1016/j.acuroe.2011.10.002, VOL. 36, NO. 6, (385-386), Online publication date: 1-Jun-2012. Juan M and Climent M (2012) Larga estabilización del cáncer renal sarcomatoide tratado con sorafenibActas Urológicas Españolas, 10.1016/j.acuro.2011.10.008, VOL. 36, NO. 6, (385-386), Online publication date: 1-Jun-2012. Haas N, Lin X, Manola J, Pins M, Liu G, McDermott D, Nanus D, Heath E, Wilding G and Dutcher J (2011) A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802Medical Oncology, 10.1007/s12032-011-9829-8, VOL. 29, NO. 2, (761-767), Online publication date: 1-Jun-2012. Shuch B, Bratslavsky G, Linehan W and Srinivasan R (2012) Sarcomatoid Renal Cell Carcinoma: A Comprehensive Review of the Biology and Current Treatment StrategiesThe Oncologist, 10.1634/theoncologist.2011-0227, VOL. 17, NO. 1, (46-54), Online publication date: 1-Jan-2012. Campbell S and Lane B (2012) Malignant Renal Tumors Campbell-Walsh Urology, 10.1016/B978-1-4160-6911-9.00049-9, (1413-1474.e33), . Geynisman D and Stadler W (2012) Variant Renal Cell Carcinoma Histologies: Therapeutic Considerations Kidney Cancer, 10.1007/978-3-642-21858-3_17, (249-264), . Dutcher J and Nanus D (2010) Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapyMedical Oncology, 10.1007/s12032-010-9649-2, VOL. 28, NO. 4, (1530-1533), Online publication date: 1-Dec-2011. Diamond E, Akhtar N, Tagawa S and Nanus D (2011) Evidence-based therapy of non-clear-cell and sarcomatoid renal cell carcinoma Targeted Therapies for Renal Cell Carcinoma, 10.2217/ebo.11.39, (110-119), Online publication date: 1-Oct-2011. Molina A, Tickoo S, Ishill N, Trinos M, Schwartz L, Patil S, Feldman D, Reuter V, Russo P and Motzer R (2011) Sarcomatoid-variant Renal Cell CarcinomaAmerican Journal of Clinical Oncology, 10.1097/COC.0b013e3181f47aa4, VOL. 34, NO. 5, (454-459), Online publication date: 1-Oct-2011. Pagliaro L, Tannir N, Sircar K and Jonasch E (2014) Systemic therapy for sarcomatoid renal cell carcinomaExpert Review of Anticancer Therapy, 10.1586/era.11.39, VOL. 11, NO. 6, (913-920), Online publication date: 1-Jun-2011. Sánchez P, Calvo E and Durán I (2011) Non-clear cell advanced kidney cancerAnti-Cancer Drugs, 10.1097/01.cad.0000390767.85658.83, VOL. 22, NO. Supplement 1, (S9-S14), Online publication date: 1-Jan-2011. Shuch B, Said J, LaRochelle J, Zhou Y, Li G, Klatte T, Pouliot F, Kabbinavar F, Belldegrun A and Pantuck A (2010) Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapyCancer, 10.1002/cncr.24768, VOL. 116, NO. 3, (616-624), Online publication date: 1-Feb-2010. Négrier S (2010) Rein Tumeurs malignes rares, 10.1007/978-2-287-72070-3_87, (549-552), . Yan B, Mackinnon A and Al-Ahmadie H (2009) Recent Developments in the Pathology of Renal Tumors: Morphology and Molecular Characteristics of Select EntitiesArchives of Pathology & Laboratory Medicine, 10.5858/133.7.1026, VOL. 133, NO. 7, (1026-1032), Online publication date: 1-Jul-2009. Golshayan A, George S, Heng D, Elson P, Wood L, Mekhail T, Garcia J, Aydin H, Zhou M, Bukowski R and Rini B (2009) Metastatic Sarcomatoid Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted TherapyJournal of Clinical Oncology, 10.1200/JCO.2008.18.0000, VOL. 27, NO. 2, (235-241), Online publication date: 10-Jan-2009. Matin S (2008) Surgical and Medical Treatment Interventional Oncology, 10.1017/CBO9780511722226.033, (377-399) Grothey E, Sartor O and Bukowski R (2008) Highlights from: The 2008 Genitourinary Cancers Symposium; February 14-16, 2008; San Francisco, CAClinical Genitourinary Cancer, 10.1016/S1558-7673(11)70045-3, VOL. 6, NO. 1, (9-14), Online publication date: 1-Mar-2008. Hugec V and Dutcher J (2008) Management of Patients with Pathologic Variants of Renal Cell Carcinoma: Papillary, Collecting Duct, Medullary and Chromophobe Carcinoma, and Sarcomatoid Differentiation Clinical Management of Renal Tumors, 10.1007/978-1-60327-149-3_32, (529-544), . Tickoo S, Alden D, Olgac S, Fine S, Russo P, Kondagunta G, Motzer R and Reuter V (2018) Immunohistochemical Expression of Hypoxia Inducible Factor-1α and its Downstream Molecules in Sarcomatoid Renal Cell CarcinomaJournal of Urology, VOL. 177, NO. 4, (1258-1263), Online publication date: 1-Apr-2007. David K, Milowsky M and Nanus D (2006) Chemotherapy for Non–Clear-Cell Renal Cell CarcinomaClinical Genitourinary Cancer, 10.3816/CGC.2006.n.005, VOL. 4, NO. 4, (263-268), Online publication date: 1-Mar-2006. Yang X, Tan M, Kim H, Ditlev J, Betten M, Png C, Kort E, Futami K, Furge K, Takahashi M, Kanayama H, Tan P, Teh B, Luan C, Wang K, Pins M, Tretiakova M, Anema J, Kahnoski R, Nicol T, Stadler W, Vogelzang N, Amato R, Seligson D, Figlin R, Belldegrun A, Rogers C and Teh B (2005) A Molecular Classification of Papillary Renal Cell CarcinomaCancer Research, 10.1158/0008-5472.CAN-05-0533, VOL. 65, NO. 13, (5628-5637), Online publication date: 1-Jul-2005. Rashid M, Welsh C, Bissada N and Chaudhary U (2005) Complete Response to Adriamycin and Ifosfamide in a Patient With Sarcomatoid Renal Cell CarcinomaAmerican Journal of Clinical Oncology, 10.1097/01.coc.0000139938.76332.6e, VOL. 28, NO. 1, (107-108), Online publication date: 1-Feb-2005. Nanus D, Garino A, Milowsky M, Larkin M and Dutcher J (2004) Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinomaCancer, 10.1002/cncr.20541, VOL. 101, NO. 7, (1545-1551), Online publication date: 1-Oct-2004. CASTILLO M, PETIT A, MELLADO B, PALACÍN A, ALCOVER J and MALLOFRÉ C (2018) C-KIT EXPRESSION IN SARCOMATOID RENAL CELL CARCINOMA: POTENTIAL THERAPY WITH IMATINIBJournal of Urology, VOL. 171, NO. 6 Part 1, (2176-2180), Online publication date: 1-Jun-2004. Volume 168 Issue 3 September 2002 Page: 959-961 Advertisement Copyright & Permissions© 2002 by American Urological Association, Inc.Keywordskidneycarcinoma, renal celldoxorubicinifosfamideneoplasm metastasisMetrics Author Information B. Escudier More articles by this author J.P. Droz More articles by this author F. Rolland More articles by this author M.J. Terrier-Lacombe More articles by this author G. Gravis More articles by this author P. Beuzeboc More articles by this author B. Chauvet More articles by this author C. Chevreau More articles by this author J.C. Eymard More articles by this author T. Lesimple More articles by this author Y. Merrouche More articles by this author S. Oudard More articles by this author F. Priou More articles by this author C. Guillemare More articles by this author S. Gourgou More articles by this author S. Culine More articles by this author Expand All Advertisement PDF downloadLoading ...
Referência(s)